Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort

European Urology

Volumn 57, Issue 2, 2010, Pages 300-309

  Fritsche, Hans Martin ^a   Burger, Maximilian ^a   Svatek, Robert S ^b   Jeldres, Claudio ^c   Karakiewicz, Pierre I ^c   Novara, Giacomo ^j   Skinner, Eila ^d   Denzinger, Stefan ^a   Fradet, Yves ^e   Isbarn, Hendrik ^d   Bastian, Patrick J ^f,k   Volkmer, Bjoern G ^g   Montorsi, Francesco ^h   Kassouf, Wassim ⁱ   Tilki, Derya ^f   Otto, Wolfgang ^a   Capitanio, Umberto ^c   Izawa, Jonathan I ^l   Ficarra, Vincenzo ^j   Lerner, Seth ^m   Sagalowsky, Arthur I ⁿ   Schoenberg, Mark ^o   Kamat, Ashish ^b   Dinney, Colin P ^b   Lotan, Yair ⁿ   Shariat, Shahrokh F ⁿ   more..

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITÉ LAVAL   (Canada)

^f UNIVERSITY OF MUNICH   (Germany)

^g UNIVERSITY OF ULM   (Germany)

^h VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

ⁱ MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^j UNIVERSITY OF PADOVA   (Italy)

^k UNIVERSITY OF BONN   (Germany)

^l UNIVERSITY OF WESTERN ONTARIO   (Canada)

^m BAYLOR COLLEGE OF MEDICINE   (United States)

ⁿ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^o JOHNS HOPKINS UNIVERSITY   (United States)

more..

Author keywords

Bladder cancer; Radical cystectomy; Recurrence; Survival; T1; Urothelial carcinoma

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANADA; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; COHORT ANALYSIS; CONTROLLED STUDY; CYSTECTOMY; EUROPE; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEX RATIO; UNITED STATES; UROGENITAL TRACT CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; CYSTECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 72149108711     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.09.024     Document Type: Article

References (47)

1. Ferlay J., Autier P., Boniol M., Heanue M., Colombet M., and Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18 (2007) 581-592
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
3. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Böhle A., and Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54 (2008) 303-314
4. Hall M.C., Chang S.S., Dalbagni G., et al. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178 (2007) 2314-2330
5. Heney N.M. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin North Am 19 (1992) 429-433
6. Heney N.M., Ahmed S., Flanagan M.J., et al. Superficial bladder cancer: progression and recurrence. J Urol 130 (1983) 1083-1086
7. Shelley MD, Court JB, Kynaston H, Wilt TJ, Coles B, Mason M. Intravesical bacillus Calmette-Guerin versus mitomycin C for Ta and T1 bladder cancer. Cochrane Database Syst Rev 2003:CD003231.
8. Huncharek M., and Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: a metaanalytic comparison of chemotherapy versus bacilli Calmette-Guerin immunotherapy. Am J Clin Oncol 27 (2004) 522-528
9. Cookson M.S., Herr H.W., Zhang Z.F., Soloway S., Sogani P.C., and Fair W.R. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158 (1997) 62-67
10. Shahin O., Thalmann G.N., Rentsch C., Mazzucchelli L., and Studer U.E. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 169 (2003) 96-100
11. Studer U.E. Radical cystectomy-often too late? Yes, but .... Eur Urol 50 (2006) 1129-1138
12. Schrier B.P., Hollander M.P., van Rhijn B.W., Kiemeney L.A., and Witjes J.A. Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy. Eur Urol 45 (2004) 292-296
13. Herr H.W., and Sogani P.C. Does early cystectomy improve the survival of patients with high risk superficial bladder tumors?. J Urol 166 (2001) 1296-1299
14. Chang B.S., Kim H.L., Yang X.J., and Steinberg G.D. Correlation between biopsy and radical cystectomy in assessing grade and depth of invasion in bladder urothelial carcinoma. Urology 57 (2001) 1063-1067
15. Van Der Meijden A., Sylvester R., Collette L., Bono A., and Ten Kate F. The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. J Urol 164 (2000) 1533-1537
16. Shariat S.F., Palapattu G.S., Karakiewicz P.I., et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 51 (2007) 137-151
17. Stein J.P. Indications for early cystectomy. Urology 18 (2000) 289-295
18. Huguet J., Crego M., Sabaté S., Salvador J., Palou J., and Villavicencio H. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Eur Urol 48 (2005) 53-59
19. Denzinger S., Fritsche H.-M., Otto W., Blana A., Wieland W.-F., and Burger M. Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?. Eur Urol 53 (2008) 146-152
20. Cheng L., Neumann R.M., Weaver A.L., et al. Grading and staging of bladder carcinoma in transurethral resection specimens: correlation with 105 matched cystectomy specimens. Am J Clin Pathol 113 (2000) 275-279
21. Ficarra V., Dalpiaz O., Alrabi N., Novara G., Galfano A., and Artibani W. Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int 95 (2005) 786-790
22. Amling C.L., Thrasher J.B., Frazier H.A., Dodge R.K., Robertson J.E., and Paulson D.F. Radical cystectomy for stages Ta, Tis and T1 transitional cell carcinoma of the bladder. J Urol 151 (1994) 31-36
23. Cheng L., Neumann R.M., Weaver A.L., et al. Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens. Am J Clin Pathol 113 (2000) 275-279
24. Freeman J.A., Esrig D., Stein J.P., et al. Radical cystectomy for high risk patients with superficial bladder cancer in the era of orthotopic urinary reconstruction. Cancer 76 (1995) 833-839
25. Masood S., Sriprasad S., Palmer J.H., and Mufti G.R. T1G3 bladder cancer-indications for early cystectomy. Int Urol Nephrol 36 (2004) 41-44
26. Wiesner C., Pfitzenmaier J., Faldum A., Gillitzer R., Melchior S.W., and Thuroff J.W. Lymph node metastases in non-muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy. BJU Int 95 (2005) 301-305
27. Dutta S.C., Smith J.A., Shappell S.B., Coffey C.S., Chang S.S., and Cookson M.S. Clinical under staging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. J Urol 166 (2001) 490-493
28. Thalmann G.N., Markwalder R., Shahin O., Burkhard F.C., Hochreiter W.W., and Studer U.E. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?. J Urol 172 (2004) 70-75
29. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162 (1999) 74-76
30. Herr H.W., and Donat S.M. Quality control in transurethral resection of bladder tumours. BJU Int 102 (2008) 1242-1246
31. Donat S.M., Shabsigh A., Savage C., et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol 55 (2009) 177-186
32. Dotan Z.A., Kavanagh K., Yossepowitch O., et al. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J Urol 178 (2007) 2308-2312
33. Nielsen M.E., Shariat S.F., Karakiewicz P.I., et al., For the Bladder Cancer Research Consortium (BCRC). Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol 51 (2007) 699-708
34. Clark P.E., Stein J.P., Groshen S.G., et al. Radical cystectomy in the elderly: comparison of clinical outcomes between younger and older patients. Cancer 104 (2005) 36-43
35. Resorlu B., Beduk Y., Baltaci S., Ergun G., and Talas H. The prognostic significance of advanced age in patients with bladder cancer treated with radical cystectomy. BJU Int 103 (2009) 480-483
36. Cai T, Bartoletti R. Re: Matthew E. Nielsen, Shahrokh F. Shariat, Pierre I. Karakiewicz, et al. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol 2007;52:611-2.
37. Thrasher J.B., Frazier H.A., Robertson J.E., et al. Clinical variables which serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 73 (1994) 1708-1715
38. Joudi F.N., Smith B.J., O'Donnell M.A., and Konety B.R. The impact of age on the response of patients with superficial bladder cancer to intravesical immunotherapy. J Urol 175 (2006) 1634-1639
39. Prout Jr. G.R., Wesley M.N., Yancik R., et al. Age and comorbidity impact surgical therapy in older bladder carcinoma patients: a population-based study. Cancer 104 (2005) 1638-1647
40. Gore J.L., Lai J., Setodji C.M., et al. Urologic Diseases in America Project. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a surveillance, epidemiology, and end results-Medicare analysis. Cancer 115 (2009) 988-996
41. Hautmann R.E. Delay of cystectomy: for whom does it really matter?. Curr Urol Rep 8 (2007) 425-426
42. Shariat S.F. Selecting patients for immediate cystectomy. Rev Urol 9 (2007) 239-241
43. Orsola A, Cecchini L, Morote J, Re: Marko Babjuk, Willem Oosterlinck, Richard Sylvester, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2009;55:e15-6.
44. Fritsche H.M., and Burger M. Management of early-invasive high-grade transitional cell carcinoma of the bladder. Minerva Urol Nefrol 60 (2008) 265-271
45. Cheng L., Neumann R.M., Weaver A.L., Spotts B.E., and Bostwick D.G. Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol 17 (1999) 3182-3187
46. Gattegno B. T1G3 bladder cancer: conservative management or cystectomy?. Eur Urol 45 (2004) 399-400
47. Shariat S.F., Bolenz C., Godoy G., et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 182 (2009) 78-84